Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ukena

Showing results (41-50 of 119) with videos related to

Pageof 12
Sort By:
Pneumologie (Stuttgart, Germany)|October 15, 2020
[Surgical Therapy for Lung Cancer: Why it Should be Performed in High Volume Centres]H Hoffmann, B Passlick, D Ukena, et al.
Biochemical Pharmacology|June 21, 1991
Zardaverine as a selective inhibitor of phosphodiesterase isozymesC Schudt, S Winder, B Müller, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 1, 1984
Ra adenosine receptors in human platelets. Characterization by 5'-N-ethylcarboxamido[3H]adenosine binding in relation to adenylate cyclase activityE Hüttemann, D Ukena, V Lenschow, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 1, 1984
Effects of N-ethylmaleimide on adenosine receptors of rat fat cells and human plateletsD Ukena, E Poeschla, E Hüttemann, et al.
Progress in Clinical and Biological Research|January 1, 1987
Adenosine receptors: development of selective agonists and antagonistsJ W Daly, K A Jacobson, D Ukena
Medizinische Klinik (Munich, Germany : 1983)|July 15, 1990
[Therapy of obstructive airway diseases. IV: medications with anti-allergic and anti-inflammatory action]D Ukena, P Schlimmer, J Vogt, et al.
Oncology Reports|April 18, 2000
Serum anti-p53 antibodies in patients with lung cancerU Mack, D Ukena, M Montenarh, et al.
Medizinische Klinik (Munich, Germany : 1983)|August 15, 1990
[Therapy of obstructive respiratory tract diseases. V: Mediator antagonists]D Ukena, P Schlimmer, J Vogt, et al.
Medizinische Klinik (Munich, Germany : 1983)|June 15, 1990
[Therapy of obstructive respiratory tract diseases. III: Glucocorticosteroids]D Ukena, P Schlimmer, J Vogt, et al.
Respiratory Medicine|July 1, 1995
Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstructionD Ukena, K Rentz, C Reiber, et al.
Pageof 12

Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
Pneumologie (Stuttgart, Germany)|October 15, 2020
[Surgical Therapy for Lung Cancer: Why it Should be Performed in High Volume Centres]H Hoffmann, B Passlick, D Ukena, et al.
Biochemical Pharmacology|June 21, 1991
Zardaverine as a selective inhibitor of phosphodiesterase isozymesC Schudt, S Winder, B Müller, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 1, 1984
Ra adenosine receptors in human platelets. Characterization by 5'-N-ethylcarboxamido[3H]adenosine binding in relation to adenylate cyclase activityE Hüttemann, D Ukena, V Lenschow, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 1, 1984
Effects of N-ethylmaleimide on adenosine receptors of rat fat cells and human plateletsD Ukena, E Poeschla, E Hüttemann, et al.
Progress in Clinical and Biological Research|January 1, 1987
Adenosine receptors: development of selective agonists and antagonistsJ W Daly, K A Jacobson, D Ukena
Medizinische Klinik (Munich, Germany : 1983)|July 15, 1990
[Therapy of obstructive airway diseases. IV: medications with anti-allergic and anti-inflammatory action]D Ukena, P Schlimmer, J Vogt, et al.
Oncology Reports|April 18, 2000
Serum anti-p53 antibodies in patients with lung cancerU Mack, D Ukena, M Montenarh, et al.
Medizinische Klinik (Munich, Germany : 1983)|August 15, 1990
[Therapy of obstructive respiratory tract diseases. V: Mediator antagonists]D Ukena, P Schlimmer, J Vogt, et al.
Medizinische Klinik (Munich, Germany : 1983)|June 15, 1990
[Therapy of obstructive respiratory tract diseases. III: Glucocorticosteroids]D Ukena, P Schlimmer, J Vogt, et al.
Respiratory Medicine|July 1, 1995
Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstructionD Ukena, K Rentz, C Reiber, et al.
Pageof 12